CD200 and B-cell chronic lymphocytic leukemia: Using Samalizumab, a recombinant humanized anti-CD200 monoclonal antibody, this study found that CD200/CD200R blockade restored CTL-mediated anti-tumor activity and reduced tumor burden in 14/23 CLL patients, though 16 patients achieved stable disease.